达格列净结合左西孟旦对经皮冠状动脉介入术后心力衰竭老年患者sST2、Ang-Ⅱ及心功能的影响

doi:10.3969/j.issn.1006-5725.2025.03.014

Abstract

Abstract:

Objective To observe the effects of dagliflozin combined with levosimendan on soluble growth-stimulated expressed gene 2 protein （sST2）， angiopoietin Ⅱ （Ang-Ⅱ） and cardiac function in elderly patients with heart failure after percutaneous coronary intervention （PCI）. Methods Eighty patients with acute myocardial infarction （AMI） admitted to the Department of Cardiology of the Affiliated Hospital of Jiangnan University from January 2021 to October 2023 were selected and divided into two groups using the lottery method. Both groups were treated with conventional therapy. The conventional group was treated with levosimendan， and the combination group with dagliflozin combined with levosimendan. Cardiac function indexes， sST2， amino-terminal brain natriuretic peptide precursor （NT-pro BNP）， renin-angiotensin-aldosterone system indexes， cardiac myosin-binding protein-C （cMyBP-C）， cardiac troponin I （cTnI）， myoglobin （MyO）， 6-minute walking distance， heart failure scoring system （Lee） score， and the Seattle Angina Scale （SAQ） score were compared between the two groups. The cumulative major adverse cardiovascular event （MACE） rate at 6-month follow-up was counted in both groups. Results The comparison of cardiac function indexes， sST2， NT-proBNP， cMyBP-C， cTnI， MyO， and renin-angiotensin-aldosterone system indexes before treatment between the two groups showed no statistical significance （P > 0.05）. Left ventricular ejection fraction （LVEF） of the two groups was higher than that before treatment， and the indexes of the renin-angiotensin-aldosterone system， end-systolic left intraventricular diameter （LVEDD）， sST2， NT-proBNP， end-diastolic left intraventricular diameter （LVESD）， cMyBP-C， cTnI， MyO， and left ventricular mass index （LVMI） were lower （P< 0.05）. LVEF was higher in the combination group than that in the conventional group after treatment， and the indexes of the renin-angiotensin-aldosterone system， sST2， cMyBP-C， LVEDD， NT-proBNP， LVESD， cTnI， MyO， and LVMI were lower than those in the conventional group （P < 0.05）. There was no statistically significant difference between the two groups in terms of 6-minute walking distance， Lee score， and SAQ score before treatment （P > 0.05）. The 6-minute walking distance and SAQ score after treatment in both groups were longer and higher than those before treatment， and the Lee score was lower （P < 0.05）. The 6-minute walking distance and SAQ score after treatment in the combination group were longer and higher， and Lee score was lower than those in the conventional group （P < 0.05）. The cumulative incidence of MACE at 6-month follow-up in the combination group was lower than that in the conventional group， and the difference was statistically significant （P < 0.05）. Two cases of gastrointestinal reactions were found in the conventional group， and one case of hypotension and three cases of gastrointestinal reactions in the combination group. Conclusion Dagliflozin combined with levosimendan improves cardiac function， modulates the renin-angiotensin-aldosterone system， and improves exercise tolerance and quality of life in patients with heart failure after PCI.

Key words: dagliflozin, levosimendan, percutaneous coronary intervention, heart failure, renin-angiotensin-aldosterone system, exercise tolerance

CLC Number:

R541.6

Guangyan WANG,Heng SU,Jun. ZHU. Effect of dagliflozin combined with levosimendan on sST2， Ang⁃Ⅱ and cardiac function in elderly patients with post⁃PCI heart failure[J]. The Journal of Practical Medicine, 2025, 41(3): 396-402.

Figures/Tables 7

Tab.1

Tab.2

Tab.3

Tab.4

Tab.5

Tab.6

Tab.7

References 25

1	OZAKI Y， HARA H， ONUMA Y， et al. CVIT expert consensus document on primary percutaneous coronary intervention （PCI） for acute myocardial infarction （AMI） update 2022［J］. Cardiovasc Interv Ther， 2022，37（1）：1-34. doi:10.1007/s12928-021-00829-9 doi: 10.1007/s12928-021-00829-9
2	SCHÄFER A， KÖNIG T， BAUERSACHS J， et al. Novel Therapeutic Strategies to Reduce Reperfusion Injury After Acute Myocardial Infarction［J］. Curr Probl Cardiol， 2022，47（12）：e101398. doi:10.1016/j.cpcardiol.2022.101398 doi: 10.1016/j.cpcardiol.2022.101398
3	BISCAGLIA S， GUIDUCCI V， ESCANED J， et al. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.［J］ N Engl J Med， 2023，389（10）：889-898. doi:10.1056/nejmoa2300468 doi: 10.1056/nejmoa2300468
4	HOSOKAWA Y， YAMAMOTO T， TARA S， et al. Comparison of Percutaneous Coronary Intervention Procedures and Outcomes for Recent and Acute ST-Elevation Myocardial Infarction［J］. Int Heart， 2023，64（3）：352-357. doi:10.1536/ihj.22-656 doi: 10.1536/ihj.22-656
5	MODZELEWSKI K L， PIPILAS A， BOSCH N A. Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure［J］. JAMA Netw Open， 2024，7（5）：e249305. doi:10.1001/jamanetworkopen.2024.9305 doi: 10.1001/jamanetworkopen.2024.9305
6	SAITO Y， OYAMA K， TSUJITA K， et al. Treatment strategies of acute myocardial infarction： Updates on revascularization， pharmacological therapy， and beyond［J］. J Cardiol， 2023，81（2）：168-178. doi:10.1016/j.jjcc.2022.07.003 doi: 10.1016/j.jjcc.2022.07.003
7	ALI A E， MAZROUA M S， ELSABAN M， et al. Effect of Dapagliflozin in Patients with Heart Failure： A Systematic Review and Meta-Analysis［J］. Glob Heart， 2023，18（1）：45-46. doi:10.5334/gh.1258 doi: 10.5334/gh.1258
8	中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南（2019）［J］.中华心血管病杂志， 2019， 47（10）：766-783. doi:10.3760/cma.j.issn.0253-3758.2019.10.003 doi: 10.3760/cma.j.issn.0253-3758.2019.10.003
9	田朝伟，陈晓辉.急性心力衰竭的诊治进展：2016 ESC 急慢性心力衰竭诊断和治疗指南［J］.中华急诊医学杂志， 2016， 25（7）：4.
10	WELKER C C， MIELKE JAR， RAMAKRISHNA H. Levosimendan and Low Cardiac Output After Cardiac Surgery： Analysis of Trial Data［J］. J Cardiothorac Vasc Anesth， 2023，37（7）：1294-1297. doi:10.1053/j.jvca.2023.03.011 doi: 10.1053/j.jvca.2023.03.011
11	COX Z L， COLLINS S P， HERNANDEZ G A， et al. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure［J］. J Am Coll Cardiol， 2024，83（14）：1295-1306. doi:10.1016/j.jacc.2024.02.009 doi: 10.1016/j.jacc.2024.02.009
12	LEE S H， JEONG M H， AHN J H， et al. Predictors of recurrent acute myocardial infarction despite successful percutaneous coronary intervention［J］. Korean J Intern Med， 2022，37（4）：777-785. doi:10.3904/kjim.2021.427 doi: 10.3904/kjim.2021.427
13	ZHOU Y， TAI S， ZHANG N， et al. Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation［J］. Biomed Pharmacother， 2023，165（1）：e115213. doi:10.1016/j.biopha.2023.115213 doi: 10.1016/j.biopha.2023.115213
14	CHARAYA K V， SCHEKOCHIKHIN D Y， NIKIFOROVA T V， et al. The use of Dapagliflozin in Acute Decompensated Heart Failure： Results of the Randomized Study［J］. Kardiologiia， 2023，63（8）：11-18. doi:10.18087/cardio.2023.8.n2221 doi: 10.18087/cardio.2023.8.n2221
15	VON LEWINSKI D， KOLESNIK E， AZIZ F， et al. Timing of SGLT2i initiation after acute myocardial infarction［J］. Cardiovasc Diabetol， 2023，22（1）：269-271. doi:10.1186/s12933-023-02000-5 doi: 10.1186/s12933-023-02000-5
16	TANASHAT M， MANASRAH A， ABOUZID M. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction： A systematic review and meta-analysis of randomized controlled trials involving 2624 patients［J］. Eur J Clin Pharmacol， 2024，80（7）：951-963. doi:10.1007/s00228-024-03660-2 doi: 10.1007/s00228-024-03660-2
17	BUTT J H， DOCHERTY K F， KOSIBOROD M N， et al. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction［J］. JACC Heart Fail，2023，11（10）：1411-1423. doi:10.1016/j.jchf.2023.04.016 doi: 10.1016/j.jchf.2023.04.016
18	陈雨意，田鹏超，冯佳禹，等. 即时检验（POCT）检测的sST2相关影响因素及其对心力衰竭的预后价值［J］. 中国循环杂志，2022，37（6）：595-601.
19	刘侃玲，张瑶. 达格列净对老年急性心肌梗死后心力衰竭患者心功能及MACE的影响［J］. 解放军医学杂志， 2023， 48（12）：1427-1432.
20	LEWIS G D， GOSCH K， COHEN L P， et al. Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction： PRESERVED-HF［J］. Circ Heart Fail，2023，16（11）：e010633. doi:10.1161/circheartfailure.123.010633 doi: 10.1161/circheartfailure.123.010633
21	盛雪，纪征，王兆翔，等. 达格列净联合诺欣妥对急性心肌梗死患者急诊介入治疗后心力衰竭的疗效［J］. 实用医学杂志，2022，38（11）：1410-1414. doi:10.3969/j.issn.1006⁃5725.2022.11.020 doi: 10.3969/j.issn.1006?5725.2022.11.020
22	CHATUR S， VADUGANATHAN M， CLAGGETT B， et al. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction： The DELIVER trial［J］. Eur Heart J， 2023，44（31）：2930-2943. doi:10.1093/eurheartj/ehad283 doi: 10.1093/eurheartj/ehad283
23	黎德恩，梅啸，李明琰. 急性ST段抬高型心肌梗死患者直接经皮冠脉介入治疗术后住院期间发生心力衰竭的危险因素［J］. 实用医学杂志，2021，37（13）：1674-1677，1683. doi:10.3969/j.issn.1006 doi: 10.3969/j.issn.1006
24	OTSUKA Y， ISHII M， IKEBE S， et al. BNP level predicts bleeding event in patients with heart failure after percutaneous coronary intervention［J］. Open Heart，2023，10（2）：e002489. doi:10.1136/openhrt-2023-002489 doi: 10.1136/openhrt-2023-002489
25	HU J， XU J， TAN X， et al. Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation［J］. Naunyn Schmiedebergs Arch Pharmacol，2023， 396（7）：1461-1470.

组别	例数	LVEF/%		LVEDD/mm		LVESD/mm		LVMI/（g/m²）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
常规组	40	36.85 ± 2.84	44.78 ± 3.05^?	61.14 ± 4.52	54.67 ± 4.06^?	45.22 ± 4.05	39.67 ± 3.65^?	114.25 ± 15.06	102.23 ± 12.07^?
结合组	40	37.05 ± 3.11	46.91 ± 3.27^?	60.97 ± 4.68	53.63 ± 3.84^?	44.93 ± 4.43	36.01 ± 3.28^?	112.98 ± 18.78	95.23 ± 10.87^?
t值		0.300	3.013	0.165	6.431	0.306	4.717	0.334	2.726
P值		0.765	0.003	0.869	0.000	0.761	0.000	0.740	0.008

组别	例数	sST2/（ng/L）		NT-proBNP/（ng/L）
组别	例数	治疗前	治疗后	治疗前	治疗后
常规组	40	100.85 ± 10.14	91.12 ± 7.46^?	3296.87 ± 478.59	642.05 ± 315.02^?
结合组	40	99.86 ± 12.07	82.03 ± 6.52^?	3311.85 ± 513.67	404.89 ± 254.56^?
t值		0.062	5.803	0.135	3.703
P值		0.951	0.000	0.893	0.000

组别	例数	cMyBP-C/（μg/L）		cTnI/（ng/mL）		MyO/（ng/mL）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
常规组	40	98.44 ± 12.58	75.58 ± 10.46^?	6.85 ± 1.44	2.85 ± 1.02^?	102.58 ± 15.83	81.01 ± 9.63^?
结合组	40	97.96 ± 14.73	67.63 ± 9.17^?	6.77 ± 1.52	1.63 ± 0.87^?	104.11 ± 18.06	70.56 ± 6.53^?
t值		0.157	3.615	0.242	5.755	0.403	5.680
P值		0.876	0.001	0.810	0.000	0.688	0.000

组别	例数	ADL/（pg/mL）		PRA/［ng/（mL·h）］		NE/（pg/mL）		Ang-Ⅱ/（pg/mL）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
常规组	40	192.42 ± 52.03	152.23 ± 43.65^?	8.67 ± 2.05	4.87 ± 1.22^?	14.75 ± 4.05	11.96 ± 3.23^?	92.05 ± 18.97	64.74 ± 14.05^?
结合组	40	188.97 ± 57.84	121.74 ± 36.58^?	8.59 ± 2.27	3.12 ± 0.89^?	14.83 ± 3.67	8.53 ± 2.11^?	90.53 ± 22.08	46.68 ± 12.17^?
t值		0.280	3.386	0.165	7.329	0.093	5.623	0.330	6.145
P值		0.780	0.001	0.869	0.000	0.926	0.000	0.742	0.000

组别	例数	6 min步行距离/m		Lee评分/分
组别	例数	治疗前	治疗后	治疗前	治疗后
常规组	40	264.52 ± 19.98	352.68 ± 24.71^?	13.25 ± 2.01	7.98 ± 1.23^?
结合组	40	258.96 ± 23.73	395.82 ± 21.50^?	13.17 ± 2.28	6.05 ± 1.17^?
t值		1.134	8.330	0.166	7.190
P值		0.260	0.000	0.868	0.000

Effect of dagliflozin combined with levosimendan on sST2， Ang⁃Ⅱ and cardiac function in elderly patients with post⁃PCI heart failure

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 25

Related Articles 15

Recommended Articles

Metrics

Comments

指标	时间	常规组（n = 40）	结合组（n = 40）	t值	P值
PL	治疗前	43.52 ± 6.25	42.87 ± 7.01	0.438	0.663
	治疗后	62.12 ± 5.28^?	71.11 ± 5.09^?	7.753	0.000
AS	治疗前	48.56 ± 8.54	49.44 ± 7.46	0.491	0.625
	治疗后	70.22 ± 6.95^?	79.78 ± 8.22^?	5.617	0.000
AF	治疗前	44.17 ± 8.51	42.97 ± 8.54	0.630	0.531
	治疗后	71.11 ± 7.56^?	82.23 ± 6.98^?	6.835	0.000
TS	治疗前	50.56 ± 7.54	51.16 ± 8.06	0.344	0.732
	治疗后	69.14 ± 8.47^?	79.63 ± 8.22^?	5.621	0.000
DP	治疗前	48.15 ± 6.65	47.59 ± 7.59	0.351	0.727
	治疗后	65.52 ± 8.19^?	76.54 ± 6.67^?	6.599	0.000

组别	例数	非致死性MI	再次血运重建	心绞痛	心衰就诊	心源性死亡	累计MACE
常规组	40	2（5.00）	1（2.50）	2（5.00）	1（2.50）	0（0.00）	6（15.00）
结合组	40	1（2.50）	0（0.00）	0（0.00）	0（0.00）	0（0.00）	1（2.50）
χ²值							3.914
P值							0.048

[1]	Ting XU,Wei HUANG,Li YANG,Hao. YU. Tumor endothelial markers1 mediate endothelial cell angiogenesis and heart failure myocardial remodeling via MAPKs pathway [J]. The Journal of Practical Medicine, 2024, 40(6): 780-786.
[2]	Yue REN,Ting TIAN,Guangsheng WEI,Ming ZHANG,Hong YU,Jie LI,Tingting DONG,Yinmei FENG,Hongchao CUI,Jiao. ZHANG. Effect of stage I comprehensive cardiac rehabilitation in patients with acute ST elevation myocardial infarctionafter emergency percutaneous coronary intervention [J]. The Journal of Practical Medicine, 2024, 40(5): 682-687.
[3]	Jianlong SHENG,Ni′na. LIU. The advanced progress on the relationship between hyperuricemia and acute myocardial infarction [J]. The Journal of Practical Medicine, 2024, 40(5): 727-730.
[4]	Ziming ZHAO,Qi MA,Jian CHEN,Yuan CHEN,Liuyi CUI,Yujie. ZHAO. Effects of semaglutide on prognosis in patients with diabetes mellitus complicated with unstable angina after percutaneous coronary intervention [J]. The Journal of Practical Medicine, 2024, 40(24): 3515-3520.
[5]	Minghua LUO,Yushan CHEN,He WANG,Huaimin GUAN,Jinhong. XIE. Effect of different methods of hemodynamic support for patients with cardiac shock complicating acute myocardial infarctionduring percutaneous coronary intervention process [J]. The Journal of Practical Medicine, 2024, 40(23): 3317-3322.
[6]	Min LI,Hongqiang ZHAO,Bin CAO,Lili LIU,Yuzhen BAO,Fengyong. YANG. Logistic regression versus CART decision tree model for predicting pulmonary infection in elderly patients with heart failure with reduced left ventricular ejection fraction [J]. The Journal of Practical Medicine, 2024, 40(23): 3349-3355.
[7]	Jie LI,Nian DENG,Guofeng SHI,Tao XU,Li YANG,Yu ZHANG,Yueyue SONG,Yuanzhu LIAO,Yixia. ZHOU. Impacts of cognitive behavioral therapy based on 5G internet of things on rehabilitation and kinesiophobia in elderly patients with coronary artery diseasefollowing PCI [J]. The Journal of Practical Medicine, 2024, 40(23): 3384-3388.
[8]	Qian ZHAO,Yan ZHANG,Qiao QIAO,Aiyun DENG. Prognostic factors of patients undergoing percutaneous coronary intervention supported by extracorporeal membrane oxygenation [J]. The Journal of Practical Medicine, 2024, 40(2): 219-224.
[9]	Xian WEN,Xianfeng ZENG,Ruiya SU. Efficacy of ivabradine combined with levosimendan in patients with acute myocardial infarction complicated with heart failure [J]. The Journal of Practical Medicine, 2024, 40(2): 242-247.
[10]	Shuping GE,Wei CHEN,Xinxin JIA,Min GAO,Min HE,Cunyu. QIN. Effect of individual exercise training as the core cardiac rehabilitation program on the rehabilitation of patients with coronary heart disease after percutaneous coronary intervention [J]. The Journal of Practical Medicine, 2024, 40(18): 2607-2611.
[11]	Yalin YANG,Yang HU,Yunhong WEI,Jie DENG,Yu. WANG. Application value and progress of heart rate recovery in indication of cardiovascular diseases [J]. The Journal of Practical Medicine, 2024, 40(18): 2660-2664.
[12]	Xiaojing CAI,Yonglian HUANG,Fei ZHOU,Xianwen. TANG. Clinical observation of umbilical moxibustion in treating chronic heart failure with Yang deficiency syndrome of blood stasis and water withdrawal [J]. The Journal of Practical Medicine, 2024, 40(14): 2021-2026.
[13]	Youming ZHANG,Junhui GONG,Hongtao ZHU. Relationship between serum CTRP12 level and in⁃stent restenosis in patients with acute myocardial infarction after percutaneous coronary intervention [J]. The Journal of Practical Medicine, 2024, 40(12): 1671-1676.
[14]	XIU Mingwen, BIAN Yuyao, RAO Shijun, HE Miao, ZHANG Yu. . Difference of bleeding risk in patients with CHD treated with different anticoagulants during PCI and its influence on number changes of CMBs [J]. The Journal of Practical Medicine, 2023, 39(5): 631-635.
[15]	Shan LONG,Xingde LIU,Tiantian LI,Yang ZOU,Haiyan ZHOU. Mechanisms and treatments of post⁃PCI anxiety and depression of patients with coronary heart disease： A review of literature [J]. The Journal of Practical Medicine, 2023, 39(21): 2850-2856.